-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
After the outbreak of the new crown epidemic, with the joint efforts of the whole world, a variety of new crown vaccines and therapeutic drugs have been developed at an unprecedented speed, and have demonstrated good preventive and therapeutic effects
On January 20, 2022, Huiping Liu, Deyu Fang and others from Northwestern University Feinberg School of Medicine published a research paper entitled: Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 in the journal Nature Communications.
Nature CommnicationsNature Commnications Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2 Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2
The research team found a type of extracellular vesicles (evACE2) carrying ACE2 protein released from the blood of patients with the new crown virus.
Extracellular vesicles that carry the ACE2 protein The more severely ill patients have higher blood levels of evACE2
These ACE2-expressing extracellular vesicles (evACE2) were able to block the infection of cells by different coronavirus variants in vitro
It is reported that Liu Huiping and Fang Deyu have founded a start-up company, Exomira, and is currently looking for industry partners to further develop the therapy
Extracellular vesicles (EVs) are collectively referred to as various vesicle structures with membrane structures released by cells.
Extracellular vesicles Extracellular vesicles are collectively referred to as various vesicle structures with membrane structures released by cells.
We know that the new coronavirus binds to the ACE2 receptor on the surface of host cells through its spike protein (S protein), thereby entering human cells and infecting
The research team found that there are ACE2-expressing extracellular vesicles (evACE2) in the blood of patients with new crowns, while healthy people do not have them, and the more severe the disease, the higher the level of evACE2 in the blood of patients with new crowns, which indicates that evACE2 is a human body The natural response to fight against Covid-19 infection
In in vitro cell experiments, evACE2 can block the binding of the new crown S protein to human cells, and its efficiency is 120 to 135 times that of recombinant human ACE2 protein
After the new coronavirus is captured by evACE2, it is either harmlessly bound around or cleared by immune cells such as macrophages, preventing it from infecting human cells
More importantly, the research team found that evACE2 is not only effective in blocking the original strain of the new coronavirus, but also effective against mutant strains such as Alpha, Beta and Delta
The research team further tested on a mouse model expressing human ACE2.
Existing Covid-19 vaccines and therapeutic antibody drugs are being challenged by mutant strains, and a new real-world study from Israel shows that a fourth booster shot is still not effective in preventing a breakthrough infection from the fast-spreading Omicron
Fourth booster shot still not effective against fast-spreading Omicron's breakthrough infection Fourth booster shot still ineffective against fast-spreading Omicron's breakthrough infection Eli Lilly and Regeneron were suspended in December 2021 Regeneron’s Covid-19 drug due to reduced efficacy against Omicron Eli Lilly and Regeneron’s Covid-19 drug suspended in December 2021 due to reduced efficacy against Omicron
Almost all COVID-19 vaccines and therapeutic antibodies are directed against the virus's S protein, and despite the constant mutation of COVID-19, they still enter and infect human cells through the ACE2 receptor
Liu Huiping (left), Fang Deyu (right)
Liu Huiping (left), Fang Deyu (right) Liu Huiping (left), Fang Deyu (right)The research team said that the current situation of the new crown pandemic is still severe, and evACE2 can be used as a potential new therapy against various mutants of the new crown and emerging mutants in the future, and even other types of coronaviruses infected by ACE2
Original source:
Original source:El-Shennawy, L.
, Hoffmann, AD, Dashzeveg, NK et al.
Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2.
Nat Commun 13, 405 (2022).
https://doi.
org/ 10.
1038/s41467-021-27893-2.
leave a message here